Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

NCT04376684 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1156

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Acute Respiratory Syndrome

Interventions

BIOLOGICAL: Otilimab
BIOLOGICAL: Placebo 1
BIOLOGICAL: Placebo 2
DRUG: Standard of care

Sponsor

GlaxoSmithKline